We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Premature Birth Predicted by Immunoassay

By LabMedica International staff writers
Posted on 03 Oct 2012
A blood test has been developed that can predict the likelihood that women with intact membranes with threatened preterm labor will deliver spontaneously within seven days of sampling.

The test is based on testing maternal serum for specific proteins, using multiplex sandwich immunoassay based on flowmetric multiplex technology, which has been used to analyze multiple inflammatory markers and neurotrophins in maternal serum in women with threatened preterm labor (PTL). More...


From 1996 to 2005, an international team working at the Sahlgrenska University Hospital (Gothenburg, Sweden) enrolled 142 healthy women without major medical problems. The women were with singleton pregnancies presenting with threatened PTL between 22 weeks plus 0-7 days and 33 weeks plus 6-7 days of gestation. The assays were based on a newly developed blood test that looks at specific proteins in the woman's blood combined with an already established examination that uses ultrasound to measure the length of the cervix.

Only proteins with detectable maternal serum levels in more than 50% of the samples were included in the analyses. Therefore, interleukins (IL) such as IL-1b, IL-2, IL-5, IL-6, and IL-8 were excluded from further analyses. The statistically highest significant values were detected for IL-10, matrix metalloproteinasis-9 (MMP-9) and migration inhibitory factor (MIF). In the prediction model, levels of maternal serum IL-10 were significantly higher in women who delivered preterm within seven days of sampling, compared with women who delivered later. The study also showed that found that levels of maternal serum chemokine (C-C motif) ligand 5 (RANTES) were statistically higher in women who delivered compared with women who delivered later.

Panagiotis Tsiartas, MD, PhDc, the senior author of the study said, "To have time to give the woman cortisone, which speeds up the development of the fetal lungs, it is common practice to delay the delivery by a couple of days with the help of tocolytic treatment or anti-contraction medications. Being able to predict if a woman who comes to the hospital with preterm contractions will actually give birth early and thereby requires follow-up and possible treatment is therefore very important. Statistically, the method can predict with 75% to 80% accuracy if a woman will give birth early." The study was published September 2012 issue of the British Journal of Obstetrics and Gynaecology.

Related Links:

Sahlgrenska University Hospital



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.